Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Adult Anaplastic Astrocytoma
NCT00003537Phase 2Completed
- Sponsor
- Burzynski Research Institute
- Start
- Apr 1995
- Primary completion
- Oct 2008
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in anaplastic astrocytoma (AA), sponsored by Burzynski Research Institute. Primary endpoint: Objective Response Rate at 12 months. Started Apr 1995; status: completed.
02
Drugs
antineoplaston A10antineoplaston AS2-1
03
Conditions
anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT00003537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003537.